TFR2

Across TCGA pan-cancer cohorts, TFR2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TFR2 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TFR2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TFR2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where TFR2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.928	0.105	.006	33	view →
LSCC	OS	Tertile	All	0.783	0.939	.017	18	view →
PDAC	OS	Median	II,III,IV	0.599	0.389	.014	4	view →
LUAD	DFS	Median	III,IV	0.432	0.925	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TFR2–CCRCC (DFS)

Open the CCRCC breakdown →